



## Clinical study for Neo-Bilirubin started at Sachsska Children's Hospital

Calmark Sweden AB (publ) announces today that a new clinical study regarding Neo-Bilirubin has been started in cooperation with the research unit at children's hospital Sachsska barnsjukhuset, part of Södersjukhuset AB, Stockholm.

The test Neo-Bilirubin was CE-marked on 21 April 2020 after satisfactory results were obtained in the research study carried out at Södersjukhuset. However, the study had to be closed prematurely due to reprioritisations of resources at Södersjukhuset as a result of the covid-19 pandemic, which meant that the study could not proceed as planned. As announced in April 2021, the situation was still the same.

"We are very happy to get started again with our collaboration with Sachsska Children's Hospital", says Anna Söderlund, CEO of Calmark. "The product is already CE-marked, but we still think it is worthwhile to conduct a new study with the customer to verify product improvements and get updated data."

*Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.*

### For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO  
Telefon: +46 70 214 98 93  
E-post: [anna.soderlund@calmark.se](mailto:anna.soderlund@calmark.se)  
[www.calmark.se](http://www.calmark.se)

**Calmark Sweden AB** is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at [www.calmark.se/eng/home](http://www.calmark.se/eng/home).